AZ asthma drug falls short in Phase 3 study
pharmafile | May 10, 2017 | News story | Research and Development | AstraZeneca, asthma, tralokinumab
AstraZeneca and its global biologics research and development arm MedImmune have announced that asthma treatment tralokinumab has failed to achieve its primary endpoint in its first Phase 3 trial.
Tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, failed to show a clinically-significant ability to reduce annual asthma exacerbation rates compared to placebo across a large sample of patients with severe asthma during the Stratos 1 trial.
Around 315 million people suffer from asthma globally, with 10% of that number suffering from a severe form of the disease – the form which tralokinumab was engineered to treat. While the drug failed to adequately deliver, AZ is now waiting on the results of a second Phase 3 trial in the hope that it proves its efficacy. The second trial data is expected to become available in the later half of the year.
“Severe asthma is a heterogeneous disease with significant unmet needs and we will now await the Stratos 2 results in the second half of 2017 to explore the potential to treat a sub-group of uncontrolled asthma patients with tralokinumab,” commented Executive Vice-President, Global Medicines Development and Chief Medical Officer Sean Bohen.
Matt Fellows
Related Content
AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that …
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …
FDA approves AstraZeneca’s Ultomiris for NMOSD treatment
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) …